Raloxifene Cuts Risk of Certain Type of Breast Cancer

A new analysis finds that those who took raloxifene (Evista) regularly over a number of years were less likely to develop invasive estrogen-receptor (ER) positive breast cancer, compared with women who did not take the drug.
U.S. News & World Report